Estadístiques de Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks
Visites totals
| views | |
|---|---|
| Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks | 31 |
Visites totals per mes
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 2 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Jain_jac_remi.pdf | 34 |
| Jain_jac_remi.pdf(legacy) | 10 |
Vistes principals per país
| views | |
|---|---|
| United States | 19 |
| Belgium | 6 |
| Germany | 2 |
| Spain | 2 |
| Argentina | 1 |
| India | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Menlo Park | 8 |
| Mountain View | 6 |
| Barcelona | 2 |
| Cupertino | 2 |
| Chennai | 1 |
| Fairfield | 1 |
| Suipacha | 1 |